NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Neogen Corporation (NEOG) Stock Analysis

Neogen Corporation (NEOG) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

NEOG

$11.83

+$0.19 (+1.63%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NEOG with… →

NEOG Key Statistics

As of Sep 4, 2026
Trading
Open
$11.47
Previous Close
$11.64
Day's Range
11.37–11.85
52-Week Range
4.90–12.85
Volume
1.26M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.76
Valuation
Market Cap
$2.58B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
31.13
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.66
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.96
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.04
Financials (FY)
Revenue (FY)
$870.40M−2.72%
Net Income (FY)
−$7.90M
Profit marginThe share of revenue left as profit after all costs and taxes.
−0.91%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
218.11M
1-Year Return
+106.10%
Dividend and dates
Earnings Date
October 8, 2026
Avg Volume
1.96M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NEOG Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+69.24%
2025−42.42%
2024−39.63%
2023+32.04%
2022−66.46%
2021+14.53%
2020+21.51%
2019+14.49%
2018−7.58%
2017+24.56%
2016 (partial year)+20.09%

As of September 4, 2026.

NEOG Revenue and Earnings by Fiscal Year

FY ends May
Fiscal yearRevenueNet incomeNet margin
2025$870.40M−$7.90M−0.9%
2024$894.70M−$1.09B−122.1%
2023$924.20M−$9.40M−1.0%
2022$822.45M−$22.87M−2.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$870.40M$408.50M−$21.60M−$7.90M−0.9%
2024$894.70M$421.40M−$1.70M−$1.09B−122.1%
2023$924.20M$463.90M$58.60M−$9.40M−1.0%
2022$822.45M$405.96M$37.52M−$22.87M−2.8%

Annual figures as reported, in the company's reporting currency. As of May 31, 2026.

NEOG Valuation vs Medical Devices Median

Median of 151 stocks
MetricNEOGMedical Devices medianvs median
P/S ratio2.962.980% below
Profit margin−0.91%−1.69%0.8 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Neogen Corporation (NEOG) carries a market capitalisation of $2.58B. It is classified in the Medical Devices industry, within the Healthcare sector. The company reports 2,636 employees.

The most recent close on file for NEOG is $11.83, dated September 4, 2026. That is +$0.19 (+1.63%) against the previous close. The 52-week range on file runs from $4.90 to $12.85. The latest close sits 141.43% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $870.40M. Against the prior fiscal year total of $894.70M, that is a change of −2.72%. The same year closed with a net loss of $7.90M. Profit margin runs at −0.91%. That is 0.8 percentage points above the Medical Devices median of −1.69%. Trailing earnings per share are −0.04.

Across the 4 fiscal years on file, revenue moves from $822.45M in 2022 to $870.40M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 31.13. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.66. Measured against sales, the shares trade at 2.96 times revenue. On price-to-sales that is 0.39% below the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.76. Annualized volatility over the trailing 10 years is 42.38%. Over the trailing twelve months the price has returned +106.10%. Measured over 10 years, that is −6.37% a year compounded.

Growth & Income

No dividend is on file for NEOG.

2026 is still running; the price is +69.24% year to date. The strongest complete calendar year on file is 2023 at +32.04%; the weakest is 2022 at −66.46%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Neogen Corporation (NEOG) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Neogen Corporation NEOG $2.58B —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Neogen Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Neogen Corporation

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns for food producers and processors. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems used for administering antibiotics and vaccines under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin, used in dogs to assist in managing pyoderma; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis on the results from multiple locations over extended periods. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

Visit website →